Recruiting · registry status

Chamomile capsules in Parkinson's

Researchers are studying chamomile capsules and measuring their effects over four weeks. Benefits remain to be established.

Testing a treatment or activity · Study reference: IRCT20220421054601N1

Plain-language introduction written with AI from the registry; not independently checked by a clinician. Read the original details below ↓

This registry record was last updated over six months ago, or its update date is missing. Recruitment may have changed. Confirm with the team before making plans.

Open the official registry record ↗

Follow this study

Looking for volunteers

Start (reported date): 2022-05-31

Planned dates can move. A study finishing does not tell us when a paper will be published.

No results summary has been confirmed in the registry records we imported. See connected papers below; we keep checking after recruitment ends.

Changes we have recorded

2026-10-11 — recruiting

These are dates we observed a change, not necessarily the dates it happened.

Papers connected to this study

No connected paper has been found yet. The tracker checks the growing library for study identifiers and registry-linked publications.

Who can join?

Age range not listed · Ask the team who can join

These are starting points, not the full rules. The research team can tell you whether the study is right for your situation.

Read all the rules for taking part

Sex eligibility reported by registry: both

Inclusion criteria: No allergies to chamomile or its derivatives Ability to communicate verbally and respond to study tools Dont use anticoagulants (such as heparin, warfarin, aspirin and Plavix) Non-dependence on drugs (including drugs, alcohol, painkillers, antidepressants and hypnotics) No asthma, cancer, insulin-dependent diabetes mellitus and systemic lupus erythematosus, heart failure and mental, hepatic or renal disorders, no use of anticoagulants (heparin, warfarin, aspirin and Plavix), no use of hypnotics And drugs. (Because the capsule used in this study is herbal, it may interfere with drugs with chemical compounds.) Exclusion criteria: Reluctance of the patient to continue cooperation Non-continuous use of medication as prescribed The occurrence of allergies in the patient The patient should stop consuming chamomile extract for any reason before the end of the intervention period

Full study name & original research details

Official study title

The effect of chamomile extract on motor function and quality of life in patients with Parkinson disease

Short title used by the registry

""Evaluation of the effect of chamomile in Parkinson's patients""

Original description

Intervention: Intervention 1: Intervention group: Chamomile capsules (200 mg) will be taken twice a day (morning and night) for 28 consecutive days. The dose of chamomile was considered with the advice of a pharmacist and based on similar studies, including the study of Adib et al., 200 mg. And only after randomly dividing the patients into control and intervention groups, the researcher will provide a specific number of chamomile extract capsules in box A and a certain number of placebo capsules in box B, and then the doctor will give each patient a number It will give a specific capsule from each box and then record the patient's details and whether the patient received the box A or B capsule. The Assessment Scale (SPES / SCOPA) and the Quality of Life Score of the Parkinson's Patients' Quality of Life Questionnaire (PDQ-39) are used to assess motor performance. After 28 days and after taking the capsules, patients will go to the doctor's office and the quality of life questionnaire and the scale of patients' motor function will be done by a specialist doctor in the office. Intervention 2: Control group: Placebo capsules (200 mg) will be taken twice a day (morning and night) for 28 consecutive days. Due to the fact that the present study is double-blind, the specialist physician and patients are not aware of the type of capsule used and only the researcher after randomly dividing the patients into control and intervention groups, the specific number of chamomile extract capsules in box A and A specific number of placebo capsules will be given to the specialist in box B, and then the doctor will give each patient a specific number of capsules from each box, and then record the patient's details and whether the patient has received box A or B capsules. ???. The Assessment Scale Primary outcome: Motor function. Timepoint: Before taking the capsules and 28 days after taking the capsules daily. Method of measurement: check list: Short Parkinson's Evaluation Scale/Scales for Outcomes in Parkinson’s Disease – Motor Function. Secondary outcome: Quality of Life. Timepoint: Before taking the capsules and 28 days after taking the capsules daily. Method of measurement: Quality of Life Questionnaire in Parkinson's Patients (PDQ-39).

Conditions reported: Parkinson. Parkinson's disease

Registry records for this study

Records are joined using registration identifiers. Titles alone do not establish that two studies are the same.

IRCT · IRCT20220421054601N1 ↗ — Recruiting; WHO ICTRP processed 2022-06-27; checked 2026-10-14

Study type: Interventional
Interventions: Intervention 1: Intervention group: Chamomile capsules (200 mg) will be taken twice a day (morning and night) for 28 consecutive days. The dose of chamomile was considered with the advice of a pharmacist and based on similar studies, including the study of Adib et al., 200 mg. And only after randomly dividing the patients into control and intervention groups, the researcher will provide a specific number of chamomile extract capsules in box A and a certain number of placebo capsules in box B, and then the doctor will give each patient a number It will give a specific capsule from each box and then record the patient's details and whether the patient received the box A or B capsule. The Assessment Scale (SPES / SCOPA) and the Quality of Life Score of the Parkinson's Patients' Quality of Life Questionnaire (PDQ-39) are used to assess motor performance. After 28 days and after taking the capsules, patients will go to the doctor's office and the quality of life questionnaire and the scale of patients' motor function will be done by a specialist doctor in the office. Intervention 2: Control group: Placebo capsules (200 mg) will be taken twice a day (morning and night) for 28 consecutive days. Due to the fact that the present study is double-blind, the specialist physician and patients are not aware of the type of capsule used and only the researcher after randomly dividing the patients into control and intervention groups, the specific number of chamomile extract capsules in box A and A specific number of placebo capsules will be given to the specialist in box B, and then the doctor will give each patient a specific number of capsules from each box, and then record the patient's details and whether the patient has received box A or B capsules. ???. The Assessment Scale
Phases: 1-2
Sponsor: Kashan University of Medical Sciences
Start date reported by registry: 2022-05-31 (reported)

Registry updated: Not reported · Status last verified by the registry submitter: Not reported

Registry records retrieved 2026-10-14 (UTC). Individual records may have older updates. Recruitment and eligibility must be confirmed with the study team.

Contact the research team

Public study contacts supplied to the registry. Ask whether recruitment is still open and what participation involves.

Dr Seyed Ali Masoud · +98 31 5545 6645 · masoud_s_a@yahoo.com

Study locations

Site status can differ from overall study status. “Status not reported” means local availability needs confirmation. Remote participation and travel arrangements must be checked with the team.

Facility not reported

Iran (Islamic Republic of)

Status not reported

The original descriptions and participation rules come from the registry. Participation is voluntary and does not guarantee benefit.